
Product Data Sheet

Product Name: Alosetron

Cat. No.: GC13654

Chemical Properties

Cas. No. 122852-42-0

Chemical Name 5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one

SMILES CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C

Formula $C_{17}H_{18}N_4O$ M.Wt 294.35

Solubility 15mg/ml in Water Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure

Background

Alosetron (GR 68755) is a Serotonin 5HT₃-receptor antagonist that is used in treatment of irritable bowel syndrome. IC₅₀ Value: Target: 5-HT Receptor. Alosetron has an antagonist action on the 5-HT₃ receptors of the enteric nervous system of the gastrointestinal tract. While being a 5-HT₃ antagonist like ondansetron, it is not classified or approved as an antiemetic. Since stimulation of 5-HT₃ receptors is positively correlated with gastrointestinal motility, alosetron's 5-HT₃ antagonism slows the movement of fecal matter through the large intestine, increasing the extent to which water is absorbed, and decreasing the moisture and volume of the remaining waste products. From Wikipedia.

References:

- [1]. Alosetron: an effective treatment for diarrhea-predominant irritable bowel syndrome By Harris, Lucinda A.; Chang, Lin From Women's Health (2007), 3(1), 15-27.
- [2]. Cremonini F, Nicandro JP, Atkinson V, Shringarpure R, Chuang E, Lembo

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

A. Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS. *Aliment Pharmacol Ther.* 2012 Sep;36(5):437-48. doi: 10.1111/j.1365-2036.2012.05208.x.

[3]. Lucak S. Irritable bowel syndrome and ischemic colitis: evidence supporting the increased use of alosetron. *Therap Adv Gastroenterol.* 2012 Jul;5(4):215-8.

[4]. Nicandro JP, Shin P, Chuang E. Evaluation of treatment continuation with alosetron by IBS-D severity criteria. *Curr Med Res Opin.* 2012 Mar;28(3):449-56.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA